Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorFernández Montes, Ana
dc.contributor.authorElez Fernandez, Mª Elena
dc.contributor.authorVivancos Prellezo, Ana
dc.contributor.authorMartínez, N.
dc.contributor.authorGonzález, P.
dc.contributor.authorCovela, M.
dc.date.accessioned2022-09-06T12:27:43Z
dc.date.available2022-09-06T12:27:43Z
dc.date.issued2022-06
dc.identifier.citationFernández Montes A, Élez E, Vivancos A, Martínez N, González P, Covela M, et al. Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer. Clin Transl Oncol. 2022 Jun;24:1209–14.
dc.identifier.issn1699-3055
dc.identifier.urihttp://hdl.handle.net/11351/8037
dc.descriptionCirculating tumor DNA; Liquid biopsy; Metastatic colorectal cancer
dc.description.abstractPurpose Some patients with histologically confirmed primary mCRC and mutated RAS reported undetectable RAS mutant clones in plasma after receiving anti-VEGF treatment. The aim was to prospectively assess it with its potential therapeutic implications. Methods RAS mutant genes in solid biopsy (before first-line treatment: FOLFOX/CAPOX + bevacizumab) were compared in liquid biopsy (before second-line treatment: panitumumab + FOLFIRI), using Idylla™ system. Discordant results between solid/liquid biopsies were assessed by the next-generation sequencing (NGS) test (solid/liquid biopsies). Results Twenty-three patients were assessed (seven had RAS mutant discrepancies between solid/liquid biopsies). The NGS test confirmed that 3/23 (13%) patients had undetectable RAS mutant clones in liquid biopsy and 3/23 (13%) presented discrepancies in solid biopsy (Idylla™ system vs. NGS test). Conclusion Thirteen percentage of patients had undetectable RAS mutant clones in liquid biopsy after first-line treatment. However, some discrepancies between solid and liquid biopsies have been observed. These results suggest a need to improve accuracy of RAS analyses, especially in solid biopsies.
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofseriesClinical and Translational Oncology;24
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectCòlon - Càncer
dc.subjectRecte - Càncer
dc.subjectClonatge molecular
dc.subject.meshColorectal Neoplasms
dc.subject.meshClone Cells
dc.subject.meshMutation
dc.titleMonitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1007/s12094-021-02767-7
dc.subject.decsneoplasias colorrectales
dc.subject.decscélulas clonales
dc.subject.decsmutación
dc.relation.publishversionhttps://doi.org/10.1007/s12094-021-02767-7
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Fernández Montes A] Medical Oncology Department, Complexo Hospitalario Universitario de Ourense, Ourense, Spain. [Élez E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Vivancos A] Cancer Genomics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Martínez N] Medical Oncology Department, Hospital Universitario A Coruña, A Coruña, Spain. [González P] Medical Oncology Department, Hospital Universitario Álvaro Cunqueiro, Vigo, Spain. [Covela M] Medical Oncology Department, Hospital Universitario Lucus Augusti, Lugo, Spain
dc.identifier.pmid34997474
dc.identifier.wos000740217300002
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record